VWM
ZVRA icon

Vermillion Wealth Management’s Zevra Therapeutics ZVRA Stock Holding History

Vermillion Wealth Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500
Closed -$13.4K – 1577
2025
Q4 		$13.4K Hold
1,500
– – 0.01% 334
2025
Q3 		$14.3K Hold
1,500
– – ﹤0.01% 967
2025
Q2 		$13.2K Hold
1,500
– – 0.01% 310
2025
Q1 		$11.2K Buy
+1,500
New +$11.9K ﹤0.01% 840

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Vermillion Wealth Management's ZVRA Position: Q1 2026 in Review

Vermillion Wealth Management sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 1,500 shares — an estimated $13.4K sold.

Vermillion Wealth Management first reported a position in ZVRA in Q1 2025 and held it in 4 quarters. The position peaked at $14.3K in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Vermillion Wealth Management reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 1,500 Zevra Therapeutics shares in Q1 2026, an estimated $13.4K.
  • Vermillion Wealth Management first reported a position in Zevra Therapeutics in Q1 2025 and held it in 4 quarters.
  • Vermillion Wealth Management's Zevra Therapeutics position peaked at $14.3K in Q3 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Vermillion Wealth Management's 13F filing for Q1 2026, filed 17 Apr 2026.